Lite Strategy (LITS) vs Telomir Pharmaceuticals (TELO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lite Strategy (LITS) has outperformed Telomir Pharmaceuticals (TELO) over the past year, losing 52.8% versus a loss of 71.6%. Telomir Pharmaceuticals is the larger company by market cap ($26.8 million vs $24.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LITS | TELO |
|---|---|---|
| Share price | $0.8026 | $0.364 |
| Market cap | $23.99M | $26.82M |
| 1-day change | -4.03% | -17.24% |
| YTD return | -39.20% | -72.63% |
| 1-year return | -52.79% | -71.56% |
| 5-year return | -98.46% | — |
| EPS (TTM) | $-1.38 | $-0.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-71.15M | $-10.41M |
| 52-week high | $1.99 | $1.58 |
| 52-week low | $0.69 | $0.353 |
| Distance from 52-week high | -59.67% | -76.96% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +998.90% |
| Average volume | 524.33K | 126.14K |
| Shares outstanding | 29.88M | 73.68M |
| Employees | 5 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LITS has outperformed TELO by 18.8 percentage points over the past year.
About Lite Strategy
LITS stock →Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Telomir Pharmaceuticals
TELO stock →Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.
Health Care · Biotechnology: Pharmaceutical Preparations
LITS vs TELO FAQ
Which is bigger, Lite Strategy or Telomir Pharmaceuticals?
Telomir Pharmaceuticals (TELO) is larger, with a market capitalization of $26.82M compared with $23.99M for Lite Strategy (LITS).
Which stock has performed better over the past year, LITS or TELO?
LITS returned -52.79% over the past 12 months, compared with -71.56% for TELO (price return, excluding dividends). Past performance does not predict future results.
Are Lite Strategy and Telomir Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.